Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review

Table 1 General characteristics of studies

Ref.	Locations	Study design	No. of participants in teplizumab group	No. participants in placebo group	Mean age in teplizumab group	Mean age in placebo group	Male sex% teplizumab	Male sex% placebo
Ramos et al[17], 2023	United States, Canada, Europe	RCT	217	111	12	12.3	54.8	62.2
Herold et al[18], 2019	United States, Canada, Australia, Germany	RCT	44	32	14	13	57	53
Herold et al[16], 2013	United States	RCT	52	25	12.7	12.3	53.8	64
Herold et al[19], 2013	United States	RCT	33	27	12.9	12	52	63
Sherry et al[20], 2011	United States, Canada, Europe	RCT	209	99	18.5	18.2	62.8	62.2

RCT: Randomized controlled trial.